Cronos is expanding its presence in Israel’s cannabis market

The Canadian cannabis company, Cronos, began marketing cannabis from the Peace Naturals brand it owns in Israeli pharmacies. The first shipment of one of its products, Original GC, came from Canada, and it was further produced at the company’s farm.

Cronos, which manages the cannabis farm at Kibbutz Gan Shmuel, started marketing one of its products this Monday, the first Original GC, in pharmacies all over the country, three years after the report on cooperation between the two countries.

If you want to know more about cannabis, how Canada is expanding its cannabis business in Israel, and to find out the latest cannabis news, download the Hemp.im mobile application.

The company aims to conquer the cannabis market in Israel with its new product

Original GC contains about 17% THC according to lab tests and the Canadian company has cataloged it in the T20 / C4 category. First available at the pharmacies, the product was sold for the highest price range – $80.75 (NIS 279) per pack of 10 grams.

The product is marketed under the Peace Naturals series, a subsidiary of Cronos Canada which is considered a successful and well-known brand worldwide. It recently arrived in Israel in a delivery of cannabis inflorescences from Canada, along with cuttings that will allow the continuation of the therapeutic sequence after the import inventory ends.

Cronos will soon launch additional products in Israel under the Peace Naturals brand, such as Infinity, Dream Haze, and GS Kush, which are currently growing in the company’s farm.

One of the most prominent cannabis companies has its eyes set on Israel

Cronos trades on the Canadian stock exchange worth about $2 billion and is one of the most prominent cannabis corporations in the world. Apart from Pease Naturals, it has full and partial ownership of a host of companies and cannabis brands such as In The Zone, ABcann, Hydropothecary, Cove, Evergreen, and more.

Initially, about three years ago, the company hoped to succeed in producing medical cannabis at low costs of up to $0.43 (NIS 1.5) per gram, but according to the high pricing given to the first product, $80.75 (NIS 279) per pack, it appeared that the company was not up to the challenge.

According to the agreement between Cronos and kibbutz Gan Shmuel, the Canadian company owns 70% of the kibbutz’s greenhouse growth and cultivation plants, as well as 90% of the production system, the plant to be established and the rest of the distribution chain. The two agreed to produce up to 5 tons of cannabis per year.

“Not only will we produce quality cannabis at the best price in the world, but the establishment of the system in Israel will also allow us to stand on the international front of research and entrepreneurship in the field,” said Cronos CEO, who awaits for export abroad.

According to Phys Natures, the new Original GC “can help patients deal with anxiety, depression, fatigue, and chronic pain. Patients who consume original Jesse cannabis claim that the effect after using the product is invigorating and stimulating.”

The company also noted that the dominant terpenes in the original Jesse are Limonene, Myrcene, and Caryophyllene, and therefore its taste will be lemon with touches of mango, eucalyptus, and cloves. According to the company, it is suitable for day use.

__

(Featured image by Michael Moriarty from Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in קנאביס, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.